-
Heart Rhythm Sep 2022
Topics: Adrenergic beta-Antagonists; Female; Humans; Infant; Long QT Syndrome; Pregnancy
PubMed: 35700907
DOI: 10.1016/j.hrthm.2022.06.009 -
Lancet (London, England) Mar 1977
Topics: Adrenergic beta-Antagonists; Blood Pressure; Body Weight; Humans; Hypertension
PubMed: 65624
DOI: 10.1016/s0140-6736(77)91389-7 -
Nihon Rinsho. Japanese Journal of... Apr 1992
Review
Topics: Adrenergic beta-Antagonists; Amino Acid Sequence; Antihypertensive Agents; Humans; Liver; Molecular Sequence Data; Molecular Structure; Stereoisomerism
PubMed: 1353122
DOI: No ID Found -
Current Cardiology Reports Mar 2001beta-Adrenergic receptor blockade has been conclusively proven to increase survival and morbidity in patients with heart failure. Hospitalization rate decreases and... (Comparative Study)
Comparative Study Review
beta-Adrenergic receptor blockade has been conclusively proven to increase survival and morbidity in patients with heart failure. Hospitalization rate decreases and patients feel better after receiving beta-blockers. Furthermore, this benefit is observed in a wide range of patients. The beta-blockers bisoprolol, metoprolol, and carvedilol have been extensively evaluated in heart failure patients. These drugs all show marked benefit. Bucindolol, an investigational beta-blocker, showed only mild improvement in survival in patients with heart failure. The beta-blockers differ regarding beta-selectivity, vasodilation properties, and perhaps other ancillary properties. At present, the importance and consequences of these differences are unknown.
Topics: Adrenergic beta-Antagonists; Heart Failure; Humans
PubMed: 11177669
DOI: 10.1007/s11886-001-0038-5 -
American Heart Journal May 1980
Review
Topics: Adrenergic beta-Antagonists; Binding Sites; Blood Pressure; Half-Life; Humans; Myocardial Infarction
PubMed: 6102840
DOI: 10.1016/0002-8703(80)90741-3 -
Drugs Jun 1990beta-Blockers are effective in reducing the blood pressure of many patients with systemic hypertension. They differ in terms of the presence or absence of intrinsic... (Review)
Review
beta-Blockers are effective in reducing the blood pressure of many patients with systemic hypertension. They differ in terms of the presence or absence of intrinsic sympathomimetic activity, membrane-stabilising activity, beta 1-selectivity, alpha-blocking properties, and relative potency and duration of action. All beta-blockers appear to have blood pressure lowering effects. The choice of which beta-blocker to use in an individual patient is determined by the pharmacodynamic and pharmacokinetic differences between the drugs in conjunction with the patient's other medical condition(s). This review discusses the practical use of beta-blockers and provides rational suggestions for which drug(s) to use in selected patient groups (Black, elderly, postinfarction, diabetes, renal disease, obstructive lung disease, elevated lipid levels, coexisting angina, and left ventricular hypertrophy).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Humans; Hypertension; Middle Aged
PubMed: 1973382
DOI: 10.2165/00003495-199039060-00005 -
Postgraduate Medicine Jan 2009Beta-blockers (beta-blockers) have demonstrated their value across the cardiovascular disease spectrum. Beta-blockers effectively lower blood pressure in patients with... (Review)
Review
Beta-blockers (beta-blockers) have demonstrated their value across the cardiovascular disease spectrum. Beta-blockers effectively lower blood pressure in patients with hypertension and provide symptomatic or mortality benefits in patients with heart failure and in post-myocardial infarction patients. However, despite their utility, beta-blockers remain underused. There have been recent concerns that beta-blockers as a class are not as effective as once thought in uncomplicated hypertension due to a relatively weak effect on reduction of stroke and the absence of an effect on coronary heart disease when compared with placebo or no treatment. Underuse can, in part, be related to tolerability concerns. Beta-blockers have been traditionally associated with side effects including depression, fatigue, sexual dysfunction, and cold extremities, which limit their acceptance by patients and physicians and may lead to discontinuation of therapy. Because of inherent heterogeneity of the beta-blocker class in terms of adrenergic receptor selectivity, intrinsic sympathomimetic activity, and vasodilatory activity, these agents vary in tolerability profile. Recently, more attention has been focused on the third-generation vasodilatory beta-blockers (ie, carvedilol, labetalol, and nebivolol), with the recognition that these agents may diverge in meaningful ways from the traditional beta-blockers. By examining the differences among members of the beta-blocker class, it may be possible to determine whether and which tolerability issues are indeed a class effect of beta-blockers or whether these agents should be evaluated on a case-by-case basis.
Topics: Adrenergic beta-Antagonists; Cardiovascular Diseases; Drug Interactions; Drug Tolerance; Humans; Hypertension; Meta-Analysis as Topic; Practice Guidelines as Topic; Randomized Controlled Trials as Topic
PubMed: 19179810
DOI: 10.3810/pgm.2009.01.1951 -
Singapore Medical Journal Oct 2021
Topics: Adrenergic beta-Antagonists; Electrocardiography; Humans
PubMed: 35001123
DOI: 10.11622/smedj.2021201 -
Journal of Chromatographic Science Sep 2013β-Adrenergic blockers represent a very important class of drugs that are used worldwide for treating various cardiac diseases. The present article describes the... (Review)
Review
β-Adrenergic blockers represent a very important class of drugs that are used worldwide for treating various cardiac diseases. The present article describes the state-of-the art of analyses of β-adrenergic blockers using high-performance liquid chromatography (HPLC). Sample preparation techniques such as liquid-liquid extraction, solid-phase extraction and solid-phase microextraction have been discussed, which are essential prior to HPLC analysis. Additionally, applications of liquid chromatography coupled with tandem mass spectrometry are included. HPLC methods have been reported to include 0.6-26 min as the run times and 0.01 ng/mL to 25 µg/mL as detection limits. The most commonly used columns were C18 with various buffers as the mobile phases, along with various organic modifiers. The optimization of HPLC conditions has been discussed. It has been observed that the reported methods are quite satisfactory for the analyses of β-adrenergic blockers in biological samples. Future perspectives in the hyphenation of solid-phase microextraction-nano-liquid chromatography-tandem mass spectrometry have also been highlighted to achieve detections at nanogram and picogram levels. The present article is very useful for academicians, scientists, drug and pharmaceutical personnel and government regulatory authorities.
Topics: Adrenergic beta-Antagonists; Chromatography, High Pressure Liquid; Humans; Limit of Detection; Liquid-Liquid Extraction; Reproducibility of Results; Solid Phase Extraction; Tandem Mass Spectrometry
PubMed: 23619556
DOI: 10.1093/chromsci/bmt030 -
Journal of the Royal College of... Oct 1976
Review
Topics: Adrenergic beta-Antagonists; Heart; Hemodynamics; Humans; Kinetics; Receptors, Adrenergic, beta
PubMed: 10437
DOI: No ID Found